High-grade gliomas show distinct biology across age and sex Proteogenomic analysis of brain tumors identified potential treatment targets and prognostic markers that differed across age, developmental stage, and sex. Written byBree Foster, PhD

High-grade gliomas show distinct biology across age and sex Proteogenomic analysis of brain tumors identified potential treatment targets and prognostic markers that differed across age, developmental stage, and sex. Written byBree Foster, PhD High-grade gliomas (HGGs) are highly aggressive primary brain tumors, with a 5-year survival rate below 10 percent. Recent genomic and epigenomic profiling studies have revealed key distinctions between adult HGG and pediatric HGG, suggesting they are biologically distinct diseases. Reflecting these differences, the 2021 WHO Classification of Tumors of the Central Nervous System made major changes to the classification of HGGs, separating pediatric and adult tumors into distinct categories. However, this leaves a less clearly defined group in between: adolescents and young adults (AYA), whose tumors can fall between the biological profiles of pediatric and adult disease. https://www.drugdiscoverynews.com/high-grade-gliomas-show-distinct-biology-across-age-and-sex-17544